Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination With Intravenous Pembrolizumab Therapy in Patients With Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer

Trial Profile

A Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination With Intravenous Pembrolizumab Therapy in Patients With Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Tavokinogene telsaplasmid (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms KEYNOTE-890
  • Sponsors OncoSec Medical
  • Most Recent Events

    • 11 Dec 2018 According to an OncoSec Medical media release, five patients have been enrolled into the trial.
    • 13 Nov 2018 According to an OncoSec Medical media release, initial project overview for this study will be presented at the 2018 San Antonio Breast Cancer Symposium (SABCS; 4-8 Dec 2018 in San Antonio, Texas).
    • 07 Nov 2018 According to an OncoSec Medical media release, first patient has been treated in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top